Article Sidebar
Published:
Feb 27, 2009Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Oct-4 expression maintained stem cell properties in prostate cancer-derived CD133+MDR1+ cells
Abstract
Purpose: CD133 (prominin-1), a 5-transmembrane glycoprotein, has recently been considered an important marker that represents the subset population of cancer stem-like cells. The purpose of the present study is to isolate cancerous stem-like cells from normal healthy volunteers and prostate cancer patients (CD133+) which also express MDR1 and to ascertain the influence of Oct-4 on ‘stem-ness' and differentiation of these CD133+ cells towards epithelium. Methods: CD133+ cells were isolated using magnetic beads from normal healthy volunteers and prostate cancer patients (NV-CD133+and PC-CD133+). The isolated cells were analyzed using flow cytometry and Western blot technique for CD133, MDR1 and Oct-4. CD133+MDR1+ cells were cultured in presence and absence of antihuman Oct-4 blocking antibody. Results: PC-CD133+ cells displayed higher Oct-4 expression with the ability to self-renew and may represent a reservoir with differentiation potential for generating prostate cancer cells. Furthermore, PCCD133 + cells highly co-expressed the multiple drug-resistant marker MDR1. The treatment with Oct-4 blocking antibody can specifically block the capability of PC-CD133+ cells to differentiate into prostate
epithelial cells bearing CD57. Conclusion: PC-CD133+ cells displayed a higher Oct-4 expression with the ability to self-renew and may represent a reservoir with differentiation potentials for progression of prostate cancer. The MDR1 expression of PC-CD133+ cells in vitro and in vivo is partially due to preferential activation of Oct-4 gene expression.
Keywords: Prostate cancer, Cancer stem-like cells, Oct-4, CD133, Multi-drug resistance1 (MDR1)
Tropical Journal of Pharmaceutical Research Vol. 8 (1) 2009: pp. 3-9
